Guangdong Taiantang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
April 09, 2021 at 09:31 am EDT
Share
Guangdong Taiantang Pharmaceutical Co., Ltd. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was CNY 3,581.948 million compared to CNY 4,013.155 million a year ago. Operating income was CNY 42.279 million compared to CNY 127.424 million a year ago. Net income was CNY 22.225 million compared to CNY 96.093 million a year ago. Basic earnings per share from continuing operations was CNY 0.03 compared to CNY 0.13 a year ago.
Guangdong Taiantang Pharmaceutical Co Ltd is a company mainly engaged in the manufacturing of Chinese patent medicines and the primary processing of Chinese medicinal materials. The Company operates five segments. Chinese Patent Medicines Manufacturing Business segment is mainly responsible for the production and wholesale of Pibao cream, Qilin pill, Xinbao pill, Xinxin pill, Tongqiao Yixin pill, etc. Primary Processing Business segment of the traditional Chinese medicine materials is mainly responsible for planting, primary processing and sales of the ginseng and traditional Chinese medicine materials. Drug Wholesale and Retail Business segment is mainly responsible for the wholesale and retail of drugs and medical devices. Health Industry Development and Products Sales segment is mainly responsible for the development and sales of health concept real estate products. Medical Services segment is mainly responsible for the in-depth development of medical and elderly care services.
GUANGDONG TAIANTANG PHARMACEUTICAL CO., LTD. 
